Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAXAIR vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular c AMP.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Prevention and treatment of bronchospasm in patients with reversible obstructive airway disease (e.g., asthma, COPD)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Primarily hepatic via glucuronidation and sulfate conjugation; also metabolized by catechol-O-methyltransferase (COMT).
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
55–70%, primarily to albumin.
Approximately 70% bound to plasma proteins, primarily albumin.
2.0–2.5 L/kg; indicates extensive distribution into tissues.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Inhalation: approximately 20–30% of the delivered dose reaches the systemic circulation; oral bioavailability is <1% due to first-pass metabolism.
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
No specific dose adjustment required; medication is primarily hepatically metabolized.
No adjustment required as drug is primarily hepatically metabolized.
No specific dose adjustment guidelines; use caution in severe hepatic impairment due to potential decreased drug clearance.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Children 6-11 years: 1-2 inhalations (170-340 mcg) via oral inhalation every 4-6 hours as needed; maximum 8 inhalations per day. Children ≥12 years: same as adult.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
No specific dose adjustment; monitor for increased sensitivity to beta-agonists (e.g., tachycardia, tremor) and concurrent diseases (e.g., cardiovascular disorders).
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
No FDA boxed warning.
None.
Paradoxical bronchospasm,Cardiovascular effects (tachycardia, arrhythmias, hypertension),Hypokalemia,Hyperglycemia,Immediate hypersensitivity reactions
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to pirbuterol or any component,Pre-existing cardiac arrhythmias (e.g., tachyarrhythmias)
Hypersensitivity to theophylline or any component of the formulation.
No specific food interactions. Avoid excessive caffeine intake as it may increase stimulant effects. Grapes, grapefruit, and grapefruit juice have no significant interaction with pirbuterol.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, maxair (pirbuterol) showed no teratogenic effects at doses up to 20 mg/kg/day in rats and up to 10 mg/kg/day in rabbits, but fetal growth retardation and increased mortality were observed at maternally toxic doses. Risk to human fetus cannot be ruled out. Use during pregnancy only if potential benefit justifies potential risk.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Unknown if pirbuterol is excreted in human milk. Due to lack of data and potential for serious adverse reactions in nursing infants, caution is advised. M/P ratio not determined.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
No specific pharmacokinetic data in pregnancy; standard dosing recommended. Beta-agonists may delay preterm labor; use with caution.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
MAXAIR (pirbuterol) is a beta-2 adrenergic agonist for asthma and COPD. Use with caution in patients with cardiovascular disorders, especially coronary insufficiency, arrhythmias, or hypertension. Monitor for paradoxical bronchospasm; if occurs, discontinue immediately. Not indicated for acute severe asthma exacerbations unless patient is closely monitored. Can cause hypokalemia, especially with concomitant use of corticosteroids or diuretics. Administer with a spacer device to improve lung deposition and reduce oral side effects.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Use only as prescribed; do not exceed recommended doses.,Rinse mouth after inhalation to prevent oral thrush.,Contact doctor if symptoms worsen or if you need more than usual doses.,Do not share the inhaler; keep it clean.,Seek immediate medical help if you experience chest pain, rapid heartbeat, or severe wheezing after use.,Inform your doctor if you have heart disease, high blood pressure, seizures, or diabetes.,Avoid using with other asthma medications without consulting your doctor.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAXAIR vs AEROLATE JR, answered by our medical review team.
MAXAIR is a Bronchodilator that works by Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular c AMP.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAXAIR and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAXAIR is: 2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAXAIR and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAXAIR is classified as Category C. FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, maxair (pirbuterol) showed no teratogenic effects at doses up to 20 mg/kg/da. AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.